Predictors of Persistent Opioid Use in Bladder Cancer Patients Undergoing Radical Cystectomy: A SEER-Medicare Analysis
July 31, 2024
UPMC Department of Urology researchers including Christopher J. Staniorski, MD; Michelle Yu, MD; Danielle Sharbaugh, MPH; Michael G. Stencel, MD; John M. Myrga, MD; Benjamin J. Davies, MD; Jonathan G. Yabes, PhD, and Bruce L. Jacobs, MD, MPH, recently published a study in Urologic Oncology titled "Predictors of persistent opioid use in bladder cancer patients undergoing radical cystectomy: A SEER-Medicare analysis."
The purpose of this study was to evaluate patient and provider characteristics that predict persistent opioid use following radical cystectomy for bladder cancer including non-opioid naïve patients.
Researchers found that non-opioid naïve patients have higher rates of post-operative opioid prescription than opioid-naïve patients. Physician prescribing practices play a role in persistent use, as initial prescription amount predicts persistent use even in non-opioid naïve patients. It is believed that significant physician variation in both prescribing practices and rates of persistent use suggest a need for standardizing practices.1
View the full study.
Reference
1. Staniorski CJ, Yu M, Sharbaugh D, Stencel MG, Myrga JM, Davies BJ, Yabes JG, Jacobs B. Predictors of persistent opioid use in bladder cancer patients undergoing radical cystectomy: A SEER-Medicare analysis. Urol Oncol. 2024 Jul;42(7):220.e21-220.e29. doi: 10.1016/j.urolonc.2024.03.010. Epub 2024 Apr 1. PMID: 38565428.
